Cannabigerol CBG Clinical Research

NOTABLE CANNABIGEROL SCIENCE:
The Pharmacological Case for Cannabigerol
Rahul Nachnani, Wesley M. Raup-Konsavage, and Kent E. Vrana | Journal of Pharmacology and Experimental Therapeutics February 2021, 376 (2) 204-212 | Full Text 
Benefits of VCE-003.2, a cannabigerol quinone derivative, against inflammation-driven neuronal deterioration in experimental Parkinson’s disease: possible involvement of different binding sites at the PPARγ receptor
Concepción García, María Gómez-Cañas, Sonia Burgaz, Belén Palomares, Yolanda Gómez-Gálvez, Cristina Palomo-Garo, Sara Campo, Joel Ferrer-Hernández, Carolina Pavicic, Carmen Navarrete, M. Luz Bellido, Moisés García-Arencibia, M. Ruth Pazos, Eduardo Muñoz, Javier Fernández-Ruiz | Journal of Neuroinflammation Volume 15, Article No: 19 (2018) | Full Text 
Colon carcinogenesis is inhibited by the TRPM8 antagonist cannabigerol, a Cannabis-derived non-psychotropic cannabinoid
Francesca Borrelli, Ester Pagano, Barbara Romano, Stefania Panzera, Francesco Maiello, Diana Coppola, Luciano De Petrocellis, Lorena Buono, Pierangelo Orlando, Angelo A. Izzo | Carcinogenesis, Volume 35, Issue 12, December 2014 | Full Text 
Beneficial effect of the non-psychotropic plant cannabinoid cannabigerol on experimental inflammatory bowel disease
Francesca Borrellia, Ines Fasolino, Barbara Romano, Raffaele Capasso, Francesco Maiello, Diana Coppola, Pierangelo Orlando, Giovanni Battista, Ester Pagano, Vincenzo Di Marzo. Angelo A. Izzo | Biochemical Pharmacology Volume 85, Issue 9, 1 May 2013, Pages 1306-1316 | Full Text 
A Cannabigerol Quinone Alleviates Neuroinflammation in a Chronic Model of Multiple Sclerosis
Aitor G. Granja, Francisco Carrillo-Salinas, Alberto Pagani, María Gómez-Cañas, Roberto Negri, Carmen Navarrete, Miriam Mecha, Leyre Mestre, Bend L. Fiebich, Irene Cantarero, Marco A. Calzado, Maria L. Bellido, Javier Fernandez-Ruiz, Giovanni Appendino, Carmen Guaza, Eduardo Muñoz | Journal of Neuroimmune Pharmacology Volume 7, pages 1002–1016 (2012) | Full Text 
Evidence that the plant cannabinoid cannabigerol is a highly potent α2-adrenoceptor agonist and moderately potent 5HT1A receptor antagonist
MG Cascio, LA Gauson, LA Stevenson, RA Ross, RG Pertwee | January 19, 2010 | British Journal of Pharmacology | Full Text 